

Trogarzo[™] (ibalizumab-uiyk) – New orphan drug approval

- On March 6, 2018, the <u>FDA announced</u> the approval of <u>Theratechnologies</u> and <u>TaiMed Biologics' Trogarzo (ibalizumab-uiyk)</u>, in combination with other antiretroviral(s) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant (MDR) HIV-1 infection failing their current antiretroviral regimen.
- Approximately 25,000 Americans with HIV are currently MDR. About 12,000 of them are in urgent need of a new treatment option because their current treatment regimen is failing them and their viral load has risen to detectable levels, jeopardizing their health and making HIV transmittable.
- Trogarzo is the first biologic drug in a new class of antiretroviral medications. It is a HIV-1 inhibitor that binds to CD4+ receptors on host cells and blocks the HIV virus from infecting the cells.
- The efficacy of Trogarzo was demonstrated in study of 40 heavily treatment-experienced HIV-infected patients with MDR HIV-1. Fifty-three percent of the participants had previously been treated with 10 or more antiretroviral drugs.
 - Eighty-three percent (95% CI: 67%, 93%) of patients achieved the study's primary endpoint, at least a 0.5 log₁₀ (or 70%) viral load reduction from baseline seven days after receiving a 2,000 mg loading dose of Trogarzo vs. 3% (95% CI: 0.06%, 13%) of patients achieving a viral load reduction from baseline prior to receiving Trogarzo therapy.
 - The average viral load reduction after 24 weeks was 1.6 log₁₀ with 43% of patients achieving undetectable viral loads.
- A warning and precaution of Trogarzo is immune reconstitution inflammatory syndrome.
- The most common adverse reactions (≥ 5%) with Trogarzo use were diarrhea, dizziness, nausea and rash.
- The recommended dosage of Trogarzo is administered intravenously as a single loading dose of 2,000 mg followed by a maintenance dose of 800 mg every 2 weeks after dilution in 250 mL of 0.9% sodium chloride injection.
- Patients can get assistance and expert support regarding their Trogarzo therapy by contacting THERA patient support[™] at 1-833-23-THERA (84372).
- The annual wholesale acquisition cost of Trogarzo will be \$118,000.
- Theratechnologies plans to launch Trogarzo within the next six weeks. Trogarzo will be available as a single-dose 2 mL vial containing 200 mg/1.33 mL.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.